China Pharma (CPHI) vs Lite Strategy (LITS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Lite Strategy (LITS) has outperformed China Pharma (CPHI) over the past year, losing 48.2% versus a loss of 56.6%. Over five years, LITS leads with a -97.8% price change compared with -99.7% for CPHI. China Pharma is the larger company by market cap ($41.5 million vs $36.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CPHI | LITS |
|---|---|---|
| Share price | $0.9645 | $1.21 |
| Market cap | $41.49M | $36.64M |
| 1-day change | +13.43% | -5.10% |
| YTD return | -29.75% | -3.79% |
| 1-year return | -56.63% | -48.16% |
| 5-year return | -99.69% | -97.82% |
| EPS (TTM) | $-0.42 | $-2.06 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $19.19 | $2.97 |
| 52-week low | $0.38 | $0.69 |
| Distance from 52-week high | -94.97% | -59.43% |
| Average volume | 5.47M | 448.62K |
| Shares outstanding | 43.02M | 30.41M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
CPHI vs LITS FAQ
Which is bigger, China Pharma or Lite Strategy?
China Pharma (CPHI) is larger, with a market capitalization of $41.49M compared with $36.64M for Lite Strategy (LITS).
Which stock has performed better over the past year, CPHI or LITS?
LITS returned -48.16% over the past 12 months, compared with -56.63% for CPHI (price return, excluding dividends). Past performance does not predict future results.
Are China Pharma and Lite Strategy in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.